




health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Reference: 2023/02/16/EDP/01

Enquiries:

Stock queries:

Ms Babalwa Melitafa

E-mail: Babalwa.Melitafa@health.gov.za

Clinical queries:

Essential Drugs Programme

E-mail: SAEDP@health.gov.za

NOTICE: RECOMMENDED THERAPEUTIC ALTERNATIVE FOR BROMOCRIPTINE TABLETS

The Adult Hospital Level (2019 edition) Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) currently recommends the use of bromocriptine tablets for the management of micro and macro prolactinoma. The contracted supplier of bromocriptine tablets, Pharmicare Limited, has indicated that due to manufacturing constraints, there is a current supply interruption, which is expected to continue until June 2023. As Pharmicare Limited is the sole supplier of bromocriptine tablets in South Africa, a therapeutic alternative is required for this period of supply interruption.

Until the supply of bromocriptine tablets normalises, the STGs and EML recommends the following therapeutic alternative for this indication:

Indications: Adult Hospital Level (2019)	Current recommendation in STGs and EML	Therapeutic alternative
Prolactinoma	Dopamine agonist therapy: <ul style="list-style-type: none"> • Bromocriptine, oral, 1.25 mg at bedtime with a snack <ul style="list-style-type: none"> ○ Initial maintenance dose: increase dose to 2.5 mg 12 hourly with food and check prolactin 4 weeks later. ○ Higher doses may be needed. ○ GIT side effects are minimised by giving doses with food. ○ If total dose of 10 mg does not normalise prolactin, refer. 	<ul style="list-style-type: none"> • Cabergoline, oral <ul style="list-style-type: none"> ○ <u>Microprolactinoma</u>: initiate at 0.5 mg orally weekly or 0.25 mg orally twice weekly. ○ <u>Macroprolactinoma</u>: initiate at 0.5 mg orally twice weekly. ○ Escalate dose according to plasma prolactin response, after discussion with an endocrinologist.

For all other causes of hyperprolactinemia please refer to an endocrinologist

Procurement details of recommended alternatives:

NSN	Product	Supplier	Contract
180348494	Cabergoline; 500mcg; Tablet; 4 Tablets	Pfizer Laboratories (Pty) Ltd	HP09-2021SD

Supply status of the recommend alternative has been confirmed.

Provinces and Healthcare Facilities are requested to distribute and communicate this information in consultation with the Pharmaceutical and Therapeutics Committees. Kindly share with all healthcare professionals and relevant stakeholders.

Kind regards

MS K JAMALOODIEN

CHIEF DIRECTOR: SECTOR WIDE PROCUREMENT

DATE: 17/2/2023